Skip To Main Content
This website is intended exclusively for healthcare professionals residing and/or working in Oman.
Campus
Campus

Inspiration and Innovation

Get inspired and stay on the cutting edge of innovation with these resources.

Sort by

Filters

Reset
  • Therapeutical Areas
  • Type of Content
LLTs Exposure Time and Major Vascular Risk Reduction

LLTs Exposure Time and Major Vascular Risk Reduction

Learn more
Improving Lipid Management for Patients Post-ACS

Improving Lipid Management for Patients Post-ACS

Learn more
Dyslipidemia performance of 2016 2019 and 2021 ESC Dyslipidemia guidelines

Dyslipidemia performance of 2016 2019 and 2021 ESC Dyslipidemia guidelines

Learn more
The role of the patient in Achieving LDL-C Target

The role of the patient in Achieving LDL-C Target

Learn more
Identifying and treating patients with high Lipidaemia risk post-ACS

Identifying and treating patients with high Lipidaemia risk post-ACS

Learn more
Effect of Alirocumab on MACE in patients with CKD

Effect of Alirocumab on MACE in patients with CKD

Learn more
Lipid management in patients with ACS/ASCVD

Lipid management in patients with ACS/ASCVD

Learn more
In hospital outcomes in young patients with AMI: Results from Gulf Coast

In hospital outcomes in young patients with AMI: Results from Gulf Coast

Learn more
Adherence and persistence analysis in patients treated with DAPT

Adherence and persistence analysis in patients treated with DAPT

Learn more
Effect of de-escalated P2Y12 inhibitor switching in dual antiplatelet therapy (DAPT)

Effect of de-escalated P2Y12 inhibitor switching in dual antiplatelet therapy (DAPT)

Learn more
Ticagrelor vs Clopidogrel in ACS patients undergoing PCI in routine clinical practice

Ticagrelor vs Clopidogrel in ACS patients undergoing PCI in routine clinical practice

Learn more
Is Clopidogrel a viable first choice P2Y12 inhibitor for DAPT after PCI?

Is Clopidogrel a viable first choice P2Y12 inhibitor for DAPT after PCI?

Learn more